Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Pik-Qi Chin, Chau-Chyun Sheu, Jong-Rung Tsai, Hsu-Liang Chang, Li-Yao Lee & Chung-Yu Chen. (2022) Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator. Patient Preference and Adherence 16, pages 875-886.
Read now
Read now
Gema Requena, Daniel Dedman, Jennifer K Quint, Rebecca E Ghosh, Rachael Williams & Jeanne M Pimenta. (2021) The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 629-642.
Read now
Read now
Jose Luis López-Campos, Laura Carrasco Hernández, Borja Ruiz-Duque, Rocio Reinoso-Arija & Candelaria Caballero-Eraso. (2021) Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 2065-2076.
Read now
Read now
Nanshan Zhong, Jinping Zheng, Sang Haak Lee, David A Lipson, Xin Du & Shunquan Wu. (2020) Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 809-819.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Jill Ohar, Robert Tosiello, Thomas Goodin & Shahin Sanjar. (2019) Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 27-37.
Read now
Read now
Giulia Parri, Dario Nieri, Maria Adelaide Roggi, Barbara Vagaggini, Alessandro Celi & Pierluigi Paggiaro. (2018) Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 12:12, pages 997-1005.
Read now
Read now
Edward Kerwin & Gary T. Ferguson. (2018) An overview of glycopyrrolate/eFlow® CS in COPD. Expert Review of Respiratory Medicine 12:6, pages 447-459.
Read now
Read now
Mohamed Ismail Abdul Aziz, Ling Eng Tan, David Bin-Chia Wu, Fiona Pearce, Gerald Seng Wee Chua, Liang Lin, Ping-Tee Tan & Kwong Ng. (2018) Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3203-3231.
Read now
Read now
Chitra Lal & Charlie Strange. (2017) Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 135-140.
Read now
Read now
Mark A. Mastrodicasa, Christopher A. Droege, Aaron M. Mulhall, Neil E. Ernst, Ralph J. Panos & Muhammad A. Zafar. (2017) Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opinion on Investigational Drugs 26:2, pages 161-174.
Read now
Read now
Articles from other publishers (29)
Akira Umeda, Hisato Shimada, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada, Katsunori Masaki, Masako Matsusaka & Koichi Fukunaga. (2023) Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. Frontiers in Physiology 14.
Crossref
Crossref
Carolina Llanos-Paez, Claire Ambery, Shuying Yang, Misba Beerahee, Elodie L. Plan & Mats O. Karlsson. (2023) Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. Journal of Pharmacokinetics and Pharmacodynamics.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Ji-Hee Youn, Mia Malmenäs, Nancy A. Risebrough, Jatin Agarwal, Maria Nassim, Raj Sharma, Chris Compton, Claus F. Vogelmeier, MeiLan K. Han & David M. G. Halpin. (2022) Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy 39:9, pages 3957-3978.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
271
299
.
Shih-Lung Cheng, Ching-Hsiung Lin, Kuo-An Chu, Kuo-Liang Chiu, Sheng-Hao Lin, Horng-Chyuan Lin, Hsin-Kuo Ko, Yung-Che Chen, Chia-Hung Chen, Chau-Chyun Sheu, Wei-Chang Huang, Tsung-Ming Yang, Yu-Feng Wei, Jung-Yien Chien, Hao-Chien Wang & Meng-Chih Lin. (2021) Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations. Journal of the Formosan Medical Association 120:10, pages 1821-1844.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov & A. V. Emelyanov. (2020) First triple therapy in one inhaler for COPD patients: treatment approach (scientific data overview). PULMONOLOGIYA 30:6, pages 813-821.
Crossref
Crossref
Alexander G. Mathioudakis, Jørgen Vestbo & Dave Singh. (2020) Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 41:3, pages 463-474.
Crossref
Crossref
François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri & Claus F. Vogelmeier. (2019) Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research 20:1.
Crossref
Crossref
Ian Naya, Lee Tombs, David A. Lipson, Isabelle Boucot & Chris Compton. (2019) Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory Research 20:1.
Crossref
Crossref
Wijdan H. Ramadan, Sarah Al Masri & John Rizk. (2019) Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal 13:11, pages 663-673.
Crossref
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Ali Abdolahinia, Mohsen Naseri, Alireza Eslaminejad, Farzaneh Ghaffari & Aliakbar Velayati. (2018) Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. Iranian Red Crescent Medical Journal 20:12.
Crossref
Crossref
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río & N. A. Risebrough. (2018) Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research 19:1.
Crossref
Crossref
Maurice Driessen, Dhvani Shah, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine 145, pages 130-137.
Crossref
Crossref
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa & Gregory Feldman. (2018) Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulmonary Therapy 4:2, pages 171-183.
Crossref
Crossref
Ian P. Naya, Lee Tombs, David A. Lipson & Chris Compton. (2018) Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy 35:10, pages 1626-1638.
Crossref
Crossref
Aya Wail Abukwaik, Rupal Mansukhani & Mary Barna Bridgeman. (2017) Long-Acting Bronchodilator Use in the Management of Stable COPD. Annals of Pharmacotherapy 52:6, pages 562-570.
Crossref
Crossref
Emmanuel Naline, Stanislas Grassin Delyle, Hélène Salvator, Marion Brollo, Christophe Faisy, Tatiana Victoni, Charlotte Abrial & Philippe Devillier. (2018) Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulmonary Pharmacology & Therapeutics 49, pages 46-53.
Crossref
Crossref
Katya Y. J. Sion, Eline L. Huisman, Yogesh S. Punekar, Ian Naya & Afisi S. Ismaila. (2017) A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD. Pulmonary Therapy 3:2, pages 297-316.
Crossref
Crossref
Edward Kerwin, Gary T. Ferguson, Shahin Sanjar, Thomas Goodin, Anthony Yadao, Robert Fogel, Samopriyo Maitra, Biswajit Sen, Tim Ayers & Donald Banerji. (2017) Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies. Lung 195:6, pages 739-747.
Crossref
Crossref
Gregory J. Feldman, Ana R. Sousa, David A. Lipson, Lee Tombs, Neil Barnes, John H. Riley, Sadhana Patel, Ian Naya, Chris Compton & Bernardino Alcázar Navarrete. (2017) Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Advances in Therapy 34:11, pages 2518-2533.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
Kesavan Suresh Babu & Jaymin Bhagwanji Morjaria. (2017) Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease 8:4-5, pages 81-91.
Crossref
Crossref
Swati Gulati & J. Michael Wells. (2017) Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs 77:6, pages 651-670.
Crossref
Crossref
Joy Creaser-Thomas, Vignesh Rajasundaram & Gwyneth A Davies. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
161
171
.
Kai M. Beeh. (2016) The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases 79:4, pages 241.
Crossref
Crossref